UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2021
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg Boulevard 12
DK-2900 Hellerup
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Ascendis Pharma A/S (the “Company”) is hereby furnishing as Exhibit 99.1 the attached presentation relating to the Company’s preliminary 58-week results from the continuing open-label extension portion of the PaTH Forward Trial, a global phase 2 trial evaluating the safety, tolerability, and efficacy of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism.
The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing or furnishing of other reports or documents with the SEC or through other public disclosures.
Exhibit
| 99.1 | Company Presentation. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Ascendis Pharma A/S | ||||||
| Date: May 10, 2021 | By: | /s/ Michael Wolff Jensen | ||||
| Michael Wolff Jensen | ||||||
| Chairman and Senior Vice President, Chief Legal Officer | ||||||
Ascendis Pharma A/S TransConTM PTH – 58-Week Open-Label Extension (OLE) Update May 10, 2021 All product candidates are investigational. For investor communication only. Not for use in promotion or product commercialisation. Exhibit 99.1
Cautionary Note On Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our business strategy, prospective products, clinical trial results, product approvals and regulatory pathways, collaborations, licensing or other arrangements, the scope, progress, results and costs of developing our product candidates or any other future product candidates, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products are forward-looking statements. These forward-looking statements are based on our current expectations and beliefs, as well as assumptions concerning future events. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission, including, without limitation, our most recent Annual Report on Form 20-F filed with the SEC on March 10, 2021 particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and represents our estimates and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these statements publicly, whether as a result of new information, future events, changed circumstances or otherwise after the date of this presentation. This presentation concerns product candidates that are or have been under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authorities. These product candidates are currently limited by U.S. Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © May 2021 Ascendis Pharma A/S.
Preliminary PaTH Forward Open-Label Extension (OLE) Data at 58 Weeks 58 subjects continue in the open-label extension beyond 58 weeks* Continued treatment with TransCon PTH demonstrated that: 91% of subjects were off standard of care therapy** Urinary calcium maintained in the normal range Bone markers trended towards the mid-normal levels Quality of life benefits measured by SF-36 continued within normal range TransCon PTH was well-tolerated at all doses administered No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events (TEAEs) led to discontinuation of study drug No change to the safety profile in the OLE portion of the study Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. *As of May 7, 2021. **Not taking active vitamin D and taking ≤600 mg/day of calcium supplements. Preliminary data support TransCon PTH as a potential hormone replacement therapy for adult HP
OLE starts PaTH Forward OLE Mean Active Vitamin D Dose TransCon PTH enabled discontinuation of active vitamin D within two weeks of treatment initiation Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. Mean Active Vitamin D Dose µg/day (± SE) Weeks
OLE starts PaTH Forward OLE Mean Calcium Supplement Dose TransCon PTH enabled rapid and continuous calcium supplement reduction; 40 of 58 subjects were taking 0 mg, and 53 of 58 subjects were taking 0 to 600 mg at week 58 Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. Mean Calcium Dose mg/day (± SE) Weeks
Mean Calcium Corrected for Albumin mg/dL (± SE) PaTH Forward OLE Mean Serum Calcium and Mean 24-Hour Urine Calcium Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. ULN = Upper limit of normal. Mean 24-hour Urine Calcium mg/24hr (± SE) Mean 24-hour urine calcium normalized while maintaining normal mean serum calcium Mean Serum Calcium Mean 24-hour Urine Calcium Weeks ULN (men) ULN (women) Normal range
PaTH Forward OLE SF-36® Health Survey Domain Mean Scores (SD) - Continued Normalization of Quality of Life Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. Green: Means above lower limit of population norm (47) All TransCon PTH (N = 59) SF-36 Domain Baseline Week 26 Week 58 Physical Function 46 (10) 51 (6) 51 (6) Role Physical 42 (10) 50 (7) 50 (8) Bodily Pain 45 (10) 50 (9) 50 (8) General Health 43 (10) 51 (8) 51 (9) Vitality 43 (11) 53 (8) 51 (10) Social Functioning 43 (10) 52 (6) 52 (7) Role Emotional 43 (13) 50 (7) 49 (8) Mental Health 46 (9) 52 (7) 50 (9) Physical Component Summary 44 (11) 50 (8) 51 (8) Mental Component Summary 44 (11) 52 (8) 50 (9)
OLE starts OLE starts PaTH Forward OLE - P1NP and CTx Bone Markers Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. Procollagen 1N-Terminal Propeptide ng/mL (± SE) TransCon PTH treatment initially increased the levels of anabolic and catabolic bone markers which were trending to mid-normal levels at 58 weeks Mean P1NP Type I Collagen C-Telopeptides ng/L (± SE) Mean CTx Weeks Weeks
Preliminary PaTH Forward OLE Safety Summary at 58 Weeks TransCon PTH was well-tolerated at all doses administered 58 out of 59 randomized subjects currently receiving TransCon PTH in OLE* No drug-related serious TEAEs were reported No TEAEs leading to discontinuation of study drug TEAEs with TransCon PTH reflect known PTH pharmacology Injections were well-tolerated using pen injector planned for commercial presentation No change to the safety profile in the OLE portion of the study Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. *As of May 7, 2021. TEAE = Treatment emergent adverse event No subjects had TEAEs related to hyper- or hypocalcemia leading to ER/urgent care visit and/or hospitalization
PaTH Forward OLE Overall TEAE Summary Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. Percentages are calculated based on the number of subjects in the Safety Population. In the severity categories, subjects are displayed for the highest severity only. An AE is considered a TEAE if it occurred after the first dose of TransCon PTH. *Headache, hypocalcemia, nausea, dizziness, paresthesia, hypercalcemia and asthenia occurred in two or more subjects. All TransCon PTH (N = 59) All TransCon PTH (N = 59) Subjects With – n (%) Treatment-Emergent Adverse Events (TEAE) 37 (63) 44 (75) Serious TEAE 2 (3) 3 (5) Severity Severe TEAE 1 (2) 2 (3) Moderate TEAE 9 (15) 10 (17) Mild TEAE 27 (46) 32 (54) Related TEAE* 14 (24) 16 (27) Serious Related TEAE 0 0 TEAE Related to Hyper- or Hypocalcemia Leading to ER/Urgent Care Visit and/or Hospitalization 0 0 TEAE Leading to Discontinuation of Study Drug 0 0 TEAE Leading to Discontinuation of Trial 0 0 TEAE Leading to Death 0 0 Up to Week 58 Up to Week 26
TransCon PTH: A Potential PTH Replacement Therapy Preliminary phase 2 PaTH Forward OLE results at 58 weeks demonstrated:* Durable benefits of TransCon PTH TransCon PTH was well-tolerated at all doses Subjects appeared to be establishing physiologic calcium metabolism* Bone markers continued to trend towards the mid-normal levels Urine calcium normal 58 subjects continue in open-label extension beyond 58 weeks** Further optimization of TransCon PTH dosing being implemented 84-week topline OLE update anticipated in Q4 2021 Expect to file CTN for Japanese adult HP phase 3 study in Q2 2021 North American and European phase 3 PaTHway Trial topline results expected Q4 2021 *Preliminary PaTH Forward OLE week 58 data from live database snapshot. Data on file. **As of May 7, 2021.